Seagen Competitors and Similar CompaniesClear all
Seagen's competitors and similar companies include Immunomedics, Rein Therapeutics, iBio and Antikor.
 Seagen Seagen (formerly known as Seattle Genetics) is a biotechnology company that develops and commercializes targeted therapies to treat cancer. |  Immunomedics Immunomedics is a developer of monoclonal antibody-based products for the targeted treatment of cancer. |  Rein Therapeutics Rein Therapeutics (formerly known as Aileron Therapeutics) is a clinical-stage biopharmaceutical company that develops medicines targeting undruggable cancer sites using its proprietary platform of stabilized cell-permeating peptides. |  Antikor Antikor is a biotechnology company that specializes in the discovery and development of small-format antibody-drug conjugates. | ||
Founding Date | Founding Date 1998 | Founding Date 1982 | Founding Date 2005 | Founding Date 2008 | Founding Date 2014 |
Type | Type Subsidiary | Type Subsidiary | Type Public | Type Public | Type Private |
Tags | |||||
Locations | Locations Bothell, US HQ Mississauga, CA Hørsholm, DK Rueil Malmaison, FR München, DE Milano, IT Schiphol, NL see more | Locations Morris Plains, US HQ | Locations Watertown, US HQ Boston, US | Locations San Diego, US HQ Bryan, US | Locations Stevenage, GB HQ |
Employees | Employees 3,25622% increase | Employees 8914% decrease | Employees 838% decrease | Employees 1630% decrease | Employees 11 |
Valuation ($) | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 90.2 m | Valuation ($) 26.2 m | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) $2b (FY, 2022) | Revenue (est.) $295k (FY, 2019) | Revenue (est.) N/A | Revenue (est.) $400k (FY, 2025) | Revenue (est.) N/A |
Cost of goods | Cost of goods $410.1m (FY, 2022) | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit $1.6b (FY, 2022) | Gross profit $295k (FY, 2019) | Gross profit N/A | Gross profit N/A | Gross profit N/A |
Net income | Net income ($610.3m) (FY, 2022) | Net income ($357.3m) (FY, 2019) | Net income ($49.9m) (FY, 2025) | Net income N/A | Net income N/A |
Operating ⚠ | |||||
Patents Issued | Patents Issued N/A | Patents Issued N/A | Patents Issued 175 (May, 2017) | Patents Issued 67 (FY, 2016) | Patents Issued N/A |
Patents Pending | Patents Pending N/A | Patents Pending N/A | Patents Pending 205 (May, 2017) | Patents Pending 19 (FY, 2016) | Patents Pending N/A |
Funding | |||||
Total funding raised | Total funding raised $ 164m | Total funding raised $ 30m | Total funding raised $ 112m | Total funding raised $ 9.3m | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Immunomedics
HQ
Morris Plains, US
Immunomedics is a developer of monoclonal antibody-based products for the targeted treatment of cancer.
View companyRein Therapeutics
HQ
Watertown, US
Employees
8↓ 38% decrease
Rein Therapeutics (formerly known as Aileron Therapeutics) is a clinical-stage biopharmaceutical company that develops medicines targeting undruggable cancer sites using its proprietary platform of stabilized cell-permeating peptides.
View companyAntikor
HQ
Stevenage, GB
Employees
11
Antikor is a biotechnology company that specializes in the discovery and development of small-format antibody-drug conjugates.
View company